Rare and Serious Diseases

Our top priority is saving and improving the lives of our patients. CSL's commitment to enhancing the quality of life for people with rare and serious diseases around the globe is reflected in our support of programs and activities for patients with rare plasma-protein related diseases, including bleeding disorders, primary immune deficiencies and Alpha 1 proteinase inhibitor deficiencies.

We collaborate with patient advocacy groups, both disease-specific and umbrella organizations, to promote quality medical care and services. We aim to improve and expand educational and outreach efforts. Through these partnerships, we strive to raise public awareness and to enhance appropriate public policies for rare diseases.

Product Inspection

CSL Behring

Saving lives and improving the quality of life for people with serious and rare conditions is what we do. Listening to our patients while continuing to introduce new innovations that address unmet medical needs or enhance current treatments is how we do it. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our patients’ needs.

Visit CSL Behring
Scanning plasma collection

CSL Plasma

CSL Plasma, a division of CSL Behring, operates one of the world's largest and most efficient plasma collection networks. CSL Plasma has more than 200 centers in the U.S. and Europe and, with its integrated manufacturing platform, operates production facilities in the U.S., Germany, Switzerland and Australia. We use the most sophisticated production methods available, meeting or exceeding stringent international safety and quality standards.

Visit CSL Plasma
Our Story

We were established in Australia in 1916 to service the health needs of a nation isolated by war.

Learn More
Job Opportunities

Join us and make history with the brightest, most passionate people from every discipline.

Learn More
Latest News

Find out what's happening now at CSL.

Learn More

Get our latest news in your inbox

First name
Last name


Thank you for subscribing
to the CSL newsletter